# Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

> **NCT07101471** · — · COMPLETED · sponsor: **NanoAlvand** · enrollment: 296 (actual)

## Conditions studied

- Alopecia Totalis/Universalis
- Alopecia Areata(AA)

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT07101471
- **Lead sponsor:** NanoAlvand
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2025-06-11
- **Final completion:** 2025-06-11
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101471, "Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07101471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*